A clinical study on the effects of teriparatide and denosumab on bone metabolism and gut microbiota in osteoporotic fracture patients

What Was Tested

This clinical trial paper looks at Teriparatide in the context of osteoporosis and bone density.

To investigate the effects of teriparatide and denosumab on bone mineral density (BMD), bone turnover markers, and gut microbiota in patients with osteoporotic fractures.

Fecal samples were collected for 16S rDNA sequencing to evaluate alterations in gut microbiota composition.

Why It Was Studied

This study compared teriparatide and denosumab in patients with osteoporotic fractures.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

All participants received concomitant calcium and vitamin D supplementation.

BMD and bone turnover markers were assessed at baseline and after a six-month treatment period.

How the Study Was Run

In design terms this was an open-label study.

Being open-label, the Teriparatide study did not mask who received what.

The methods mention a period of six months.

What Was Measured

Topics PubMed links to this paper include Bone and Bones, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Denosumab, Gastrointestinal Microbiome and Osteoporotic Fractures.

Author keywords: Bone metabolism, Gut microbiota and Teriparatide.

What This Means in Plain Language

The paper is an open-label study of Teriparatide in people with osteoporosis and bone density over six months.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Archives of osteoporosis), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.